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Abstract
In the present study, the simultaneous application of azurin gene of P. aeruginosa and MAM-A antigen on the induction 
of immune responses against breast cancer tumors was investigated in BALB/c mice. The pBudCE4.1-azurin-MAM-A 
recombinant vector was generated and prepared at a large scale. This recombinant vector alone or combined with chitosan 
nanoparticles was infused into the hip muscle of animals. Animals were divided into the “prevention” and “therapy” cat-
egories. The animals of prevention category were first, immunized by a recombinant vector and then exposed to chemical 
cancer inducers; while the animals in the therapy category were first treated with chemical compounds and then infused by 
a recombinant plasmid. The tumor tissues, infusion sites, and blood specimens were collected and examined by serologi-
cal, molecular, and histological tests. The breast tumor incidence in the infused animals by recombinant plasmid alone or 
combined with nanoparticles (in both prevention and therapy categories) compared with infused mice by empty pBudCE4.1 
vector was significantly decreased (p < 0.05). These results were supported by histological studies using H&E staining. The 
ELISA and q-real-time PCR techniques showed the range of IFN-γ, IL-12, IL-4, and IL-17A cytokines in the infused mice 
by recombinant vector alone or combined with nanoparticles compared to the healthy mice and infused animals by intact 
pBudCE4.1 were significantly increased (p < 0.05). Accordingly, the expression of the tumor markers CEA, Krt20, and Muc1 
were significantly decreased in treated mice either by the sole recombinant vector or combined with nanoparticles (p < 0.05). 
These findings indicated that pBudCE4.1-azurin-MAM-A recombinant vector plays an essential role against the formation 
and expansion of breast tumors in the animal model. In addition, this recombinant vector is safe and has the proper ability 
to stimulate the immune system. In addition, the chitosan nanoparticle represents a promising adjuvant for DNA vaccine 
delivery, which improves the immune system stimulation and boosts the vaccine performance.
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Introduction
Breast cancer is one of the most common types of cancers 
in women worldwide in all age groups. It is a second lead-
ing cause of death after lung cancer and one of the three 
most commonly occurring cancers in the world (Ly et al. 
2011; Balekouzou et al. 2016). According to the reports 
published by the World Health Organization (WHO) in the 
year 2018, the most common cancers in the world are breast 
(2.09 million cases), lung (2.09 million cases), colon and 
rectum (1.8 million cases), prostate (1.28 million cases), and 
stomach (1.03 million cases) cancers (Aragon et al. 2015; 
Bray et al. 2018). Familial and genetic histories, increasing 
age, lifestyle, geographic region, nulliparity, late age at first 
birth, pregnancy at an early and late ages, late menarche, 
early menopause, late age of menopause with high intake 
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of polyunsaturated fats, and early menstrual periods before 
age 12 years are more risk factors for breast cancer (Kruk 
2007; Anderson et al. 2014; Anjum et al. 2017). Due to the 
limitations of existing therapies for breast cancer includ-
ing surgery, radiation therapy, chemotherapy, hormone and 
biological therapies, endocrine therapy, and as well as the 
possibility of metastasis, the lack of definitive treatment in 
advanced disease, and the lack of an appropriate vaccine 
for prevention and treatment of this type of cancer, it is 
very important to find a definitive and effective therapeu-
tic method based on molecular methods and recombinant 
DNA vaccines (Li and Petrovsky 2016; Paluch-Shimon et al. 
2016; Lukong 2017). One of the vaccine strategies for the 
disease that has been reported and studied is the application 
of DNA plasmid for antigenic protein coding. This recombi-
nant plasmid is infused directly into the muscle of the animal 
to an expression of protein antigens. In addition, this type 
of vaccines is subunits and the antigen expression by this 
DNA plasmid activates both humoral and cellular immune 
response. The advantages of genetically engineered DNA 
vaccines are noninfectious, cheapness, safety, easy to grow, 
store and production, heat resistance, and long-term safety 
of application (Khan 2013; Zhang and El Zowalaty 2016). 
Thereupon, gene vaccines lead to the long-term expression 
of the antigen and beget a memory of the desired immune 
system (Felberbaum 2015). Nowadays, there is a lot of evi-
dence about the interaction between the immune system and 
breast cancer, therefore, this type of cancer has become a 
good target for research on cancer vaccine (Farkona et al. 
2016). One of the most important bacteria that its toxins and 
enzymes have been therapeutic properties is Pseudomonas 
aeruginosa (P. aeruginosa). The azurin bacteriocin in this 
bacterium is a periplasmic copper-containing protein with 
14-kDa molecular weight that consists of 128 amino acids 
(Bernardes et al. 2013; Karpiński and Adamczak 2018). This 
bacteriocin has an anticancer effect against breast cancer 
tumors via interaction with p53 and binding to the EphB2 
tyrosine kinase (extracellular receptor protein) and can pre-
vent the tumor progression (Bernardes et al. 2010; Fialho 
et al. 2016; Gao et al. 2017).
Mammaglobin-A (MAM-A) is a 10-kD secretory pro-
tein containing 93 amino acids. This protein is encoded 
by the SCGB2A2 gene and expressed in most cases of pri-
mary and metastatic human breast cancers (Soysal et al. 
2014). MAM-A through the eliciting of MAM-A-specific 
CD8 T cell in a body and due to the unique expression in 
breast cancer cells is known as a very specific molecular 
marker in breast cancer patients. In addition, this protein 
is an appropriate target for immunosuppressive therapy in 
these patients (Kim et al. 2016). Therefore, in this study, 
the encoding genes of azurin bacteriocin of P. aeruginosa 
and human MAM-A were used in the prepared recombi-
nant pBudCE4.1-azurin-MAM-A gene construct and their 
simultaneous effects on incitement of the immune system 
and breast cancer tumors in cancerous BALB/c mice were 
evaluated.
Materials and methods
pBudCE4.1‑azurin‑MAM‑A construct preparation
In this research, the recombinant pBudCE4.1-azurin-MAM-
A was designed and ordered to the Generay Biotech Co., 
Ltd. (Shanghai, China) for synthesis. In addition, the empty 
pBudCE4.1 vector was obtained from this company. For the 
expression of this recombinant vector in the eukaryotic host, 
the codon optimization of the azurin and MAM-A (target 
genes) sequences for better expression was done by Generay 
Biotech company. DNA sequencing and restriction enzy-
matic digestions by PstI, KpnI, XbaI, and XhoI were done 
for reliability and validity of artificial gene synthesis and 
pBudCE4.1-azurin-MAM-A recombinant vector generation.
The pBudCE4.1 vector possesses two different multiple 
cloning sites (MCSs) that in this study both of azurin and 
MAM-A genes were cloned independently into these sepa-
rate MCSs. The pBudCE4.1 (empty vector) has a length of 
4.6 kb and capable to express in human and animal hosts 
which has two eukaryotic promoters (human cytomegalo-
virus (CMV) and human elongation factor 1 alpha (EF-1 
alpha) promoters). Both azurin and MAM-A genes with the 
length of 1287 and 1309 bp, respectively, were inserted in 
the pBudCE4.1-azurin-MAM-A recombinant vector near 
these strong promoters to simultaneous expression of both 
genes.
Bacterial transformation and plasmid extraction
The E. coli NovaBlue strain (Novagen) was overnight cul-
tured in Luria–Bertani (LB) broth (Sigma, St. Louis, Mo. 
USA) by incubation at 37 °C with shaking at 180 rpm. The 
NovaBlue competent cells were prepared using calcium 
chloride  (CaCl2) and a brief (90 s) heat shock (42 °C) treat-
ments. These cells were used for separate transformation 
of pBudCE4.1-azurin-MAM-A and empty pBudCE4.1 vec-
tors. Then, transfected bacteria were cultured in low salt LB 
agar medium in the presence of 25 μg/mL of zeocin antibi-
otic for colony screening. The transformation accuracy was 
first confirmed by colony-polymerase chain reaction (PCR) 
screening using specific primers and then positive colonies 
were cultured into the 5 mL of LB broth containing zeocin. 
Finally, the mini-prep plasmid DNA extraction from cul-
tured bacterial cells was performed using YTA Miniprep 
Kit according to the recommendations of the manufacturer 
(Yekta Tajhiz Azma Co, Tehran, Iran). Determining the yield 
and quality of purified plasmids were measured in a ratio 
3 Biotech           (2019) 9:271  
1 3
Page 3 of 15   271 
of absorbance at 260 nm and 280 nm, using a NanoDrop 
spectrophotometer (Thermo Scientific™ NanoDrop 2000, 
Wilmington, DE, USA) according to the method described 
by Sambrook and Russell 2001. The presence of target genes 
(azurin and MAM-A) in the isolated recombinant vector was 
investigated by PCR and digestion with several restriction 
enzymes (NcoI, KpnI, ApaI, SmaI, and SacI). Each amplified 
product and digested fragments were loaded on a 2% agarose 
gel in the presence of a 1 kb DNA marker (CinnaGen, Iran) 
and were electrophoresed for 45 min at 80 V in running 
buffer (TBE 1%). The gel was visualized under UV light 
using the UVIDoc gel documentation system (Uvitec, UK) 
after an appropriate ethidium bromide (2 µg/mL) staining.
Conventional PCR of target genes
The sequences of target genes, including azurin and MAM-A 
were obtained from the National Center for Biotechnology 
Information (NCBI) GenBank sequence database. The PCR 
oligonucleotide primers for each gene were designed with 
the assistance of the computer program Oligo 4.0 (National 
Biosciences, Inc., Plymouth, MN) (Table 1). The sequence 
of each primer was compared to a query sequence of Gen-
Bank data using BLAST (Basic Local Alignment Search 
Tool) and Multiple Sequence Alignment by CLUSTALW 
(Kyoto University Bioinformatics Center; http://www.genom 
e.jp/tools /clust alw). The PCR amplification was performed 
in a final volume of 25 μL containing 1 μL of 0.2 μM dNTP 
mix, 2 μL of  MgCl2 (2 mM), 2 μL 1× PCR Buffer (all Cin-
naGen, Tehran, Iran), 1 unit (0.2 μL) of CinnaGen Taq DNA 
polymerase, 1 μL (1 µM) of each forward and reverse primer, 
and 2 μL (50 ng) of pBudCE4.1-azurin-MAM-A recombi-
nant vector. A negative control contains all reaction compo-
nents, except the template plasmid DNA. Both target genes 
were amplified in a thermal cycler (Gene Atlas G; ASTEC 
Co., Seoul, Korea). The following thermal cycling program 
was used to obtain products: initial denaturation at 94 °C for 
5 min, 35 cycles of denaturation at 94 °C for 1 min, anneal-
ing at 65 °C and 66 °C for azurin and MAM-A genes, respec-
tively, elongation at 72 °C for 50 s, and a final elongation at 
72 °C for 10 min. The PCR products were electrophoresed 
through 1% agarose gel and stained with ethidium bromide 
and finally visualized under UV light according to the pro-
cedure used previously.
Large‑scale preparation of the vectors
After transformation confirmation, the transformed bac-
terial cells were cultured in 250 mL LB broth containing 
zeocin antibiotic. Then, the bacterial culture was deposited 
and the recombinant pBudCE4.1-azurin-MAM-A plasmids 
were extracted in a large volume using a YTA Maxiprep Kit 
(Yekta Tajhiz Azma Co, Tehran, Iran) according to the man-
ufacturer’s guidelines for the vector infusions in BALB/c 
Table 1  The details of oligonucleotide primers that were used for RT-PCR and q-real-time PCR
Gene Primers name Sequences Annealing tem-
perature (°C)
Product 
length (bp)
Accession number
Azurin Azu-F 5′-ATG CTA CGT AAA CTC GCT GCC-3′ 65 292 M30389
Azu-R 5′-TGT CGT CGG GCT TCA GGT AATC-3′
MAM-A Mam-F 5′-CAG CGG CTT CCT TGA TCC TTG-3′ 65 221 NM_002411
Mam-R 5′-TGG CAT TGT CGT CTA TGA ACT CTT G-3′
IFN-γ IFN-γ-F 5′-GCC TAG CTC TGA GAC AAT GAACG-3′ 64 188 M28621
IFN-γ-R 5′-GCC AGT TCC TCC AGA TAT CCAAG-3′
IL-4 IL-4-F 5′-TCA CAG GAG AAG GGA CGC CATG-3′ 66 246 NM_021283
IL-4-R 5′-TGG ACT TGG ACT CAT TCA TGG TGC -3′
IL-12 IL-12-F 5′-TGA CAC GCC TGA AGA AGA TGAC-3′ 64 325 M86671
IL-12-R 5′-ACT GCT ACT GCT CTT GAT GTT GAA C-3′
IL-17A IL-17-F 5′-CTA CAG TGA AGG CAG CAG CGATC-3′ 66 263 NM_010552
IL-17-R 5′-CTT TCC CTC CGC ATT GAC ACAG-3′
CEA CEA-F 5′-GGC ACT AAT AAG ACT ACA ACA GGG C-3′ 64 223 X53084
CEA-R 5′-GTT CTT TGA CTG TGG TGT TGG TGA C-3′
KRT20 KRT20-F 5′-ATT CGA GGT TCA AGT CAC GGAGC-3′ 66 206 NM_023256
KRT20-R 5′-TCT GGC GTT CTG TGT CAC TCCTG-3′
Muc1 Muc1-F 5′-CCA CCA GTT CTC CAG TCC ACA GTA G-3′ 65 233 NM_013605
Muc1-R 5′-CGT CAC TTT GGT AGT AGA GAA TGG C-3′
GAPDH GAPDH-F 5′-TCC CGT AGA CAA AAT GGT GAAGG-3′ 65 261 XM_017321385
GAPDH-R 5′-ATG TTA GTG GGG TCT CGC TCCTG-3′
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mice. The optical density (OD) of purified plasmids was 
measured at a wavelength of 260/280 nm as described above.
Preparation and in vitro characterization of chitosan 
nanoparticles
Chitosan nanoparticles were synthesized via the ionic gela-
tion method and sodium tri-polyphosphate (TPP) anions. 
Based on this method, chitosan nanoparticles (Sigma-
Aldrich, USA) with low molecular weight and moderate 
were dissolved in 1% acetic acid aqueous solution at (2 mg/
mL) under the magnetic stirring at 800 rpm for 24 h incu-
bation at room temperature. The pH of this solution was 
adjusted to 5 using 0.5 M NaOH. Then, the chitosan solu-
tion was filtered by 0.45-μm Millipore filter to remove any 
unsolved chitosan. In addition, TPP solution was prepared 
at a concentration of 0.7 mg/mL by dissolving in enough 
deionized (DI) water. The pH of the solution was adjusted to 
4 with acetic acid and then was passed through a 0.2 μm Mil-
lipore filter. To prepare the chitosan nanoparticles, the TPP 
solution was slowly dropped to 50 mL of an acetic acid solu-
tion containing chitosan. Then, this solution was shacked 
on a magnetic stirrer at 800 rpm in room temperature for 
45  min. Finally, the prepared nanoparticles suspension 
were centrifuged at 14,000 rpm (4 °C) for 15 min and were 
powdered and freeze-dried using a Virtis Advantage Plus 
freeze-dryer (SP Scientific, Warminster, USA) and stored at 
4 °C. The size, surface charge, zeta potential, and Polydis-
persity Index (PDI) of the chitosan nanoparticles were deter-
mined using a Malvern Nano ZS90 Zetasizer Nanoseries 
system (Malvern Instruments, Malvern, UK). The weights 
of freeze-dried nanoparticles were also measured and the 
morphological analysis of nanoparticles was investigated by 
scanning electron microscope (SEM). One drop of lyophi-
lized chitosan nanoparticles was coated with a gold-plated 
metal and nanoparticle surface properties and their shape 
were observed using SEM. For animal infusions, an equal 
volume of both chitosan nanoparticles solution (1%) and the 
plasmid DNA solution (2000 μg/mL dissolved in PBS) were 
mixed well by pipetting and were incubated at 55 °C for 1 h.
Ethics statement and animal grouping
This study was approved by the Research Ethics Commit-
tees of the Deputy of research and technology of Islamic 
Azad University of Shahrekord Branch, Shahrekord, Iran 
on October, 10th 2017 with ethics code: IR.IAU.SHK.
REC.1397.049. The infusions were done in 78 female 
BALB/c mice with 5 weeks age and 18 g average weight. 
These animals were divided into six groups according to 
Table 2. In all treatments, six mice were considered normal 
control (healthy mice). For infusions, 1000 μg/mL of both 
Table 2  The animal groups and schedule of the treatments of BALB/c mice in this study
a Recombinant vector: pBudCE4.1-azurin-MAM-A
b DMBA and MNU: chemical compounds as cancer inducers
Group Number 
of mice
Explanation
Prevention
 A 12 Infusion by recombinant  vectora (3 times, days 0, 7, and 15) and 15 days after the last injection gavage by  DMBAb (4 
times, days 30, 51, 72, and 93) and 1 month later (day 123) infusion by  MNUb (single dose), finally follow-up within 
3 months for breast tumor formation
 B 12 Infusion by recombinant vector plus chitosan nanoparticles (3 times, days 0, 7, and 15), and 15 days after the last injec-
tion gavage by DMBA (4 times, days 30, 51, 72, and 93) and 1 month later (day 123) infusion by MNU (single dose), 
finally follow-up within 3 months for breast tumor formation
 C 12 Infusion by only pBudCE4.1 vector without target genes (pBudCE4.1) for 3 times (days 0, 7, and 15) and 15 days after 
the last injection gavage by DMBA (4 times, days 30, 51, 72, and 93) and 1 month later (day 123) infusion by MNU 
(single dose), finally follow-up within 3 months for breast tumor formation
Therapy
 D 12 Gavage by DMBA (4 times, days 0, 21, 42, and 63) and 1 month later (day 94) infusion by MNU (single dose) and 
after 3 months (follow-up for breast tumor formation) infusion by a recombinant vector (3 times, days 184, 191, and 
198)
 E 12 Gavage by DMBA (4 times, days 0, 21, 42, and 63) and 1 month later (day 94) infusion by MNU (single dose), and 
3 months later (follow-up for breast tumor formation) infusion by recombinant vector plus chitosan nanoparticles (3 
times, days 184, 191, and 198)
 F 12 Gavage by DMBA (4 times, days 0, 21, 42, and 63) and 1 month later (day 94) infusion by MNU (single dose) and 
after 3 months (follow-up for breast tumor formation) infusion by the only pBudCE4.1 vector (3 times, days 184, 
191, and 198)
Healthy mice
 G 6 Normal or healthy mice (without infusion)
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pBudCE4.1 (empty vector) and pBudCE4.1-azurin-MAM-
A plasmids was separately dissolved in PBS. IN addition, 
a 2% of chitosan nanoparticles solution was prepared in 
PBS and dissolved in 1000 μg/mL of the recombinant vec-
tor that dissolved in PBS (half as much as half). For each 
BALB/c mice in all groups, 100 μL of these DNA solutions 
(as a DNA vaccine) was infused into the quadriceps mus-
cle of animals of each group [in the form of intramuscular 
(IM) injection] according to the schedule of injections in 
Table 2. In this study, due to the synergistic effects of the 
7,12-dimethylbenz[a]anthracene (DMBA) and 1-methyl-
1-nitrosourea (MNU) in mammary carcinogenesis, these 
chemical compounds were used for induction of breast 
cancer in both prevention and therapy categories of female 
BALB/c mice. DMBA was dissolved in 100 μL of corn oil 
with a dose of 1 mg/week for gavage of each mouse until 
completing the total dose of 1, 3, 6 or 9 mg (Oliveira et al. 
2015). One month after the last DMBA gavage, a single 
dose of MNU (50 mg/kg or 1 mg for each BALB/c mice) 
dissolved in corn oil was intraperitoneally (IP) injected to 
induce the breast cancer tumors (Roomi et al. 2005; Boshra 
and Hussein 2016). All groups after the last treatment were 
followed for 3 months to investigate the breast cancer tumor 
development. At this time, in different intervals, one mouse 
in the control groups (C and F groups that infused by only 
pBudCE4.1 and exposed to the chemical compounds) was 
killed and examined for breast tumor formation to tumor 
size investigation and histological studies. All mice were 
weighed weekly and were examined until death. Finally, 
after follow-up for breast tumor formation, the mice of all 
groups [the infused mice by recombinant vector alone or 
combined with chitosan nanoparticles, and as well as intact 
plasmid (pBudCE4.1) as a control group] were killed. Then, 
the complete blood sample of each mouse was taken directly 
by needle aspiration of a heart and was separately collected 
in ethylenediaminetetraacetic acid (EDTA) tubes and nor-
mal 1.5-mL micro-tube (clot blood) for molecular and sero-
logical studies, respectively, in further tests. Afterward, the 
mice of each group were autopsied and the tumor texture 
was analyzed and compared for tumor size and histological 
analysis. In addition, the muscle of the injection site (mouse 
thigh) was removed and stored at − 70 °C for investigation 
the expression of target genes (azurin and MAM-A) of the 
recombinant vector. One part of the breast tumor tissue was 
separately obtained for RNA extraction and one slice was 
gathered in 10% formalin for histological studies.
RNA extraction and cDNA preparation
Total RNA was isolated from collected blood and homog-
enized tissue (injection site, tumor tissue, and normal tissue) 
samples of all group mice. RNA purification was carried out 
by 1 mL ice-cold RNX plus (RNX plus™ Kit Cinnagen, 
Tehran, Iran) according to the manufacturer’s instructions. 
The concentration and quality of extracted RNA was quanti-
fied using NanoDrop spectrophotometer. Each cDNA sample 
was synthesized from 2 µg of the extracted total RNA using 
both oligo dT and random hexamer mix (50 μM) according 
to the standard protocol of cDNA synthesis kit (Yekta Tajhiz 
Azma, Tehran, Iran).
Gene expression
The expression of target genes of pBudCE4.1-azurin-MAM-
A recombinant vector (azurin and MAM-A genes) in the 
mice injection sites were evaluated by reverse transcription 
PCR (RT-PCR). The RT-PCR procedure and thermal con-
ditions were the same as mentioned above except template 
DNA that was replaced by cDNA sample and the products 
were analyzed on a 1% agarose gel.
The q-real-time PCR with SYBR green detection was 
used for the survey of important cytokines [including 
interferon-γ (IFN-γ), IL-4, IL-12, and IL-17A] in the blood 
samples and tumor marker [Muc1 or Mucin 1, KRT20 
(encodes cytokeratin 20 protein), and carcinoembryonic 
antigen or CEA] expression level in the breast tumor tissues. 
As mentioned before, the expression of these tumor mark-
ers increases in the primary and advanced breast cancer, 
and they are useful and ideal molecular markers for moni-
toring of breast cancer tumors (Lacroix 2006; Kufe 2013; 
Lasa et al. 2013). The sequence of each gene was obtained 
from the GenBank sequence database of NCBI and all PCR 
primers were designed using Gene Runner version 3.05 and 
Primer Premier 5.0 software and their queries were analyzed 
by BLAST. The list of gene name and the primer sequence 
used for real-time PCR is shown in Table 1. In all q-real-
time PCR reactions, a GAPDH reference gene was used as 
an internal control for comparison and normalization of the 
gene expression level. A Corbett Rotor-Gene 6000 real-time 
rotary analyzer (Corbett, Australia) was used for amplifi-
cation and melting curve analysis. A serial dilution of the 
cDNA sample at a concentration of 1:5, 1:25, 1:125, 1:625, 
and 1:3125 were prepared and standard curve analysis of 
each primer set was done. The cDNA sample at a concen-
tration of 1:5 was suitable for q-real-time PCR amplifica-
tion. All cDNA samples using the standard curve method 
were evaluated and the q-real-time PCR was performed in 
triplicate for each gene. The reaction mixture in a 0.2-mL 
micro-tube at a final volume of 13 μL consisted of 6.5 μL 
of YTA 1× SYBR Green qPCR Mix (Yekta Tajhiz Azma, 
Tehran, Iran), 0.5 μL of each forward and reverse primer 
(2 μM), 1 μL cDNA specimen (50 ng), and 4.5 μL of dis-
tilled water. The q-real-time PCR was performed under the 
following temperature conditions: pre-denaturation at 95 °C 
for 3 min, 40–45 cycles of denaturation at 94 °C for 30 s, 
annealing (temperatures are according to Table 1 for each 
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gene) for 3 min, and elongation at 72 °C for 30 s followed 
by melting curve analysis at a temperature of 72 °C to 95 °C 
(1 °C/s). The relative expressions were monitored by Rotor-
Gene Real-time analysis software version 6.0 (Qiagen, Inc., 
Valencia, CA, USA) using the comparative Cts  (2−ΔΔCt) of 
the target and reference genes (Livak method).
Sandwich ELISA test
The enzyme-linked immunosorbent assay (ELISA) test 
was done for evaluation of the serum level of IFN-γ, IL-4, 
IL-12 (IL-12/P40), and IL-17A cytokines in all collected 
mice serum samples according to the method described by 
each ELISA kit (Hangzhou Eastbiopharm Co., Ltd., Hang-
zhou, China with Cat. No: CK-E11382 for IFN-γ; Cat. 
No: CK-E20011 for IL-4; Cat. No: CK-E90740 for IL-12, 
and Cat. No: CK-E92107 for IL-17A). Standard dilutions 
were performed at concentrations of 640 ng/L, 320 ng/L, 
160 ng/L, 80 ng/L, and 40 ng/L using original standard and 
standard diluents. All ELISA kits were based on the prin-
ciple of double-antibody sandwich technique and 40 μL 
of serum of each BALB/c mice was added to the each test 
wells. Fifteen minutes after adding the stop solution, the 
optical density (OD) of all wells of an ELISA plate was 
measured under 450  nm wavelength by Stat Fax-2100 
ELISA plate reader (Awareness Technology, Palm City, FL). 
The standard curve linear was calculated and drawn accord-
ing to the standards’ concentration and the corresponding 
OD values.
Tissue examination
In this study, after the gavage of DMBA and MNU injection, 
during and 3 months after the last treatment, all mice in each 
group were tested for breast cancer tumors and histologi-
cal studies. Mice in each group were weighed daily and the 
incidence and development of breast cancer tumors were 
examined weekly. The diameter of the tumor was measured 
with the Vernier caliper and the tumor volume was calcu-
lated according to the formula: V = 0.5a × b2 (a: is the long-
est diameter of the tumor, b: is the shortest diameter of the 
tumor). At the end of the treatment period, the animals were 
anesthetized with diethyl ether. In cancerous mice, the area 
around the tumor was shaved and splitting. Afterward, the 
tumors were completely removed in a sterile condition and 
one part of the tumor tissue was placed in 10% formalin and 
one slice was separately used for a molecular test.
Preparation of the tissue sections by microtome
Tumor tissues were processed using an automatic tissue pro-
cessor (Leica Histokinette 2000; Leica Microsystems, Wet-
zlar, Germany). All steps were carried out in accordance with 
the manufacturer’s specifications and instructions with minor 
modifications which are summarized below. After dipping 
the tissues with increasing degrees of alcohol, the clarity of 
the samples from alcohol was done using a replacement with 
xylene and then with paraffin embedding. Then, the samples 
by maintaining their orientation were molded in paraffin. Two 
pieces of molds were placed on a flat glass or stone surface 
and molten paraffin was poured into the molds. All samples 
were placed with paraffin in the form of preservation and 
the specification of each section was recorded and bonded 
to paraffin in the block. After cooling and tightening of the 
paraffin, the molds were separated from the solid paraffin 
containing the sample by a brief blow. The molds were kept 
in the refrigerator until they were cut with a microtome. The 
cutting of paraffin blocks containing the sample was prepared 
by a microtome with a thickness of 1 µm. To remove of wrin-
kles, the samples were transferred to the slide (that previously 
placed on the albumin glue) at a 30° slope on a water bath 
at 45 °C. The slides were transferred to the heater and then 
placed on a wooden board and were placed at 39 °C for 12 h 
until the samples completely stuck to the slide. One slide 
from each block was subjected for haematoxylin and eosin 
(H&E) staining for histopathological studies.
H&E staining of the tissue sections
The H&E or HE stain was used for staining of the tissue sec-
tions. Before staining, the slides were placed in the oven for 
1–2 h at 55 °C for deparaffinization. After removing the xylol 
and alcohol of the cells, a haematoxylin (Harris) solution 
was used for 20–40 min to stain of the tissue sections. Then, 
the tissue sections were washed in tap water for 1–5 min, 
until sections turn blue. The sections were differentiated in 
70% ethanol containing 1% HCl for 5 s and were washed for 
1–5 min, in tap water until turning blue. Next, the sections 
were stained by Eosin solution for 10 min and were washed 
again for 1 to 5 min in tap water and let to dehydrate, clear, 
and mount. To permanently seal the samples, the Canada 
balsam glue was used between slide and lamel and thereafter 
the slides were air-dried for 12 h to completely dry.
Statistical analysis
All experiments were run in triplicate and repeated at least 
three times. All data were entered into the Social Sciences 
software (SPSS, Inc., Chicago, IL, USA) version 20 and 
the mean difference between groups were calculated by 
independent T test or analysis of variance (ANOVA) statis-
tical methods. The graphs were prepared using GraphPad 
Prism version 5.01 for Windows (GraphPad Software, San 
Diego, CA, USA, http://www.graph pad.com). A p < 0.05 
was considered statistically significant.
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Results
Confirmation of transformation
The presence of target genes, including azurin and MAM-A 
in pBudCE4.1-azurin-MAM-A recombinant vector, was 
confirmed by Generay Biotech company using enzymatic 
digestions and DNA sequencing. The transformation 
accuracy of the recombinant vector into E. coli was veri-
fied using enzymatic digestions and indicated the success-
ful transformation of the vector into the host for increasing 
the amount of plasmid (Fig. 1).
Physicochemical characterization of chitosan 
nanoparticles for plasmid DNA delivery
In this study, the chitosan nanoparticles were used for 
better uptake of plasmid DNA. The particle size, zeta 
potential, molecular weight, particle charge, and a disper-
sion index of chitosan nanoparticles were evaluated using 
dynamic light scattering (DLS) instrument and Zetasizer 
nano ZS ZEN3600 (Malvern Malvern Zetasizer Nano ZS, 
ZEN 3600) at a wavelength of 633 nm in 25 °C. The zeta 
potential analysis of chitosan nanoparticles showed that 
these nanoparticles successfully prepared and 98.8% of 
these particles had a size of 111.7 nm, the size distribution 
of 35, and zeta potential of 20.8 mV (Fig. 2).
The morphological characteristics of freeze-dried 
chitosan nanoparticles were determined using the SEM 
electron microscope and it was found that the prepared 
chitosan nanoparticles had an orderly and homogeneous 
spherical with smooth edges (Fig. 3).
Breast tumor formation and histological 
examination of tumor tissues
In this study, the treatments of BALB/c mice by DMBA 
and MNU chemical compounds were used for induction of 
breast cancer. After DMBA gavage and MNU infusion, in 
the following period, the visceral and breast cancer tumors 
Fig. 1  The fragments of digested pBudCE4.1-azurin-MAM-A recom-
binant vector using restriction enzymes on 2% agarose gel electropho-
resis (M: 1-kb DNA molecular marker (Thermo Fisher Scientific), 
line 1: digested recombinant vector by NcoI: 220 bp, 1471 bp (con-
taining azurin gene), and 3657 bp, line 2: restricted plasmid by KpnI 
and ApaI including 590 bp, 19 bp, 368 bp (containing MAM-A gene), 
and 4371 bp, line 3: restriction fragments by SmaI and SacI: 187 bp, 
551 bp, 132 bp, 492 bp (containing azurin gene), and 3986 bp, and 
line 4: undigested recombinant plasmid (5348 bp), respectively)
Fig. 2  The particle size (left) and zeta potential distribution (right) of chitosan nanoparticles
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were observed in some animals of groups (especially in the 
control group mice (C and F) and except healthy mice with-
out any treatments). The breast tumors’ average weight and 
tumor incidence rate in mice of each group are recorded in 
Table 3. The mice that died due to the inappropriate infusion 
or other agents were excluded from the study (not more than 
10% of each group). The visceral and breast cancer tumors 
in cancerous BALB/c mice are shown in Fig. 4. The rate 
of breast tumor incidence and the mean mammary tumor 
weight in mice of the therapy category were slightly larger 
than the prevention category. The histological study of nor-
mal (healthy mice) and breast tumor tissues were investi-
gated by H&E staining. In some mice, after treatment of 
chemical compounds only inflammation of the breast tis-
sue was observed (Fig. 5). In this study, as we expected, 
the breast tumor incidence in the prevention and therapy 
groups that received the recombinant vector was very low 
(according to Table 3) and breast tissues in these categories 
were similar to the breast tissue of healthy BALB/c mice 
(Fig. 5). The H&E results confirmed the creation of breast 
cancer tumors that were induced by chemical compounds, 
especially in animals of C and F groups (not received 
pBudCE4.1-azurin-MAM-A recombinant vector).
Qualitative RT‑PCR results
After tissue separation from the injection sites of all ani-
mal groups, RNA extraction and cDNA synthesis were 
done. Then, the qualitative RT-PCR was used to confirm the 
expression of azurin and MAM-A target genes of pBudCE4.1-
azurin-MAM-A recombinant plasmid in the quadriceps mus-
cle of animals. The RT-PCR products on 1% agarose gel elec-
trophoresis revealed the DNA bands with the length size of 
292 and 221 bp for azurin and MAM-A genes, respectively. 
In the animals of both prevention and therapy categories (that 
were infused by the pBudCE4.1-azurin-MAM-A recombi-
nant vector alone or combined with the chitosan nanoparti-
cles), the expressions of both target genes were observed in 
the tissue infusion site of the animals (Fig. 6).
Serological findings
The immune stimulation was evaluated in the infused 
BALB/c mice by pBudCE4.1-azurin-MAM-A recombinant 
vector alone or combined with chitosan nanoparticles by 
Fig. 3  The SEM image of prepared chitosan nanoparticles
Table 3  The tumor incidence and average of breast tumor weight in 
the cancerous BALB/c mice in the groups of prevention and therapy 
categories compared to the healthy group
*These data compared with C and F groups were statistically signifi-
cant (p < 0.05) using one-way ANOVA analysis
a One mouse in these groups was excluded from the study for some 
unknown reasons (< 10%)
Group Number of cancerous 
mice/number of mice
Tumor 
incidence 
(%)
Mean breast tumor 
weight in cancerous 
mice (mg)
Prevention category
 A 2/11a,* 18.2 122 ± 6*
 B 1/11a,* 9.1 106 ± 2*
 C 11/12 91.7 657 ± 4
Therapy category
 D 3/12* 25 345 ± 3*
 E 2/11a,* 18.2 268 ± 5*
 F 10/11a 90.9 723 ± 7
Healthy mice
 G 0/6 0 0
Fig. 4  The creation of the 
visceral and breast cancer 
tumors in treated BALB/c mice 
by DMBA and MNU chemical 
compounds
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ELISA assay. The serum levels of IFN-γ, IL-4, IL-12, and 
IL-17A cytokines in collected serum specimens from all 
mice of each prevention and therapy classes were inves-
tigated by each specific ELISA kits. The comparisons of 
serum levels of cytokines by ELISA test showed that IFN-
γ, IL-12, and IL-17A serum levels in the infused mice by 
pBudCE4.1-azurin-MAM-A plus chitosan nanoparticles 
(B and E groups) compared to the infused mice with only 
recombinant vector (A and D groups) in both prevention 
and therapy categories increased statistically significantly 
(p < 0.05). In addition, the IL-4 serum range in A and B 
groups in prevention class compared to D and E groups in 
the therapy category increased, but the difference was not 
statistically significant (p > 0.05). In addition, the serum 
levels of these cytokines in the infused mice by only recom-
binant vector (A and D groups) and recombinant plasmid 
together with nanoparticles (B and E) compared with infused 
mice by empty pBudCE4.1 vector (C and F groups) and 
healthy mice (G group without any infusions) in both pre-
vention and therapy categories were significantly increased 
(p < 0.05) (Fig. 7).
The quantitative real‑time PCR analysis
The comparisons of the relative expression of cytokine genes 
(IFN-γ, IL-4, IL-12, and IL-17A genes) and tumor markers 
(CEA, Krt20, and Muc1 genes) after normalization via the 
reference gene (GAPDH) were done according to the Livak 
method. According to the graphs of Fig. 8, the expression of 
all cytokine genes including IFN-γ, IL-4, IL-12, and IL-17A 
in the mice of both prevention and therapy categories which 
were infused by recombinant vector alone or combined with 
chitosan nanoparticles (A, B, D, and E groups) compared 
with the infused group by empty pBudCE4.1 vector (C and 
F groups) and as well as non-infused mice (healthy mice; 
G group) elicited and significantly increased (p < 0.05). 
In addition, the results showed that the expression level 
of cytokine genes in injected mice with the recombinant 
vector first and then treated with chemical compounds (A 
and B as a prevention category) compared to the animals of 
the therapy category that were first treated with cancerous 
Breast cancer tumor Breast tissue with inflammation Normal breast tissue Recombinant vector group
A B C D
Fig. 5  The images of H&E staining of breast tissues (×200 mag-
nifying). a Tissue of breast cancer tumor, b breast tissue with only 
inflammation, c normal breast tissue (healthy mouse), and d breast 
tissue of infused mouse by pBudCE4.1-azurin-MAM-A recombinant 
vector without any tissue lesion
1000
750
500
250
Fig. 6  A 1% agarose gel electrophoresis for investigating the expres-
sion of azurin and MAM-A genes in infused muscles of BALB/c 
mice by pBudCE4.1-azurin-MAM-A recombinant vector alone and 
combined with nanoparticle in both prevention and therapy cat-
egories (lane M and M1 are 1-kb and 100  bp gene rulers (Thermo 
Fisher Scientific), respectively; lanes 1 and 2, 4, and 5: the ampli-
fied azurin gene in prevention and therapy classes, respectively; lane 
3: the infused mouse by empty pBudCE4.1 plasmid (control group); 
lane 6: healthy mouse without infusion; and lane 7: negative control 
(non-template DNA); lanes 8, 9, 11, 12: the bands of amplified MAM-
A gene in muscle of infused mice; lane 10: infused mouse by entire 
pBudCE4.1 vector; lane 13: non-infused mouse; and lane 14: nega-
tive control (without DNA), respectively)
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chemicals and then received the recombinant plasmid (D 
and E groups) increased (p < 0.05). The expression of all 
cytokine genes except IL-4 and IL-12 in infused BALB/c 
mice by pBudCE4.1-azurin-MAM-A recombinant vector 
combined with chitosan nanoparticles (B group) compared 
with the infused group by an only pBudCE4.1-azurin-MAM-
A recombinant vector (A group) increased but is not statisti-
cally significant (p > 0.05).
To verify the efficiency of the infused recombinant vector, 
the expression of mice breast tumor markers (CEA, Krt20, 
and Muc1 genes) were evaluated. The results indicated that 
CEA and Muc1 genes in the infused mice by pBudCE4.1-
azurin-MAM-A recombinant vector alone and along with 
chitosan nanoparticles (A, B, D, and E groups) compared 
with injected mice with intact vector (C and F groups 
infused by the only empty pBudCE4.1 plasmid) in both 
prevention and therapy categories significantly decreased 
(p < 0.05) and represent that the development and spread of 
tumors were inhibited. While, the expression diminution of 
Krt20 was observed in the mice that only received recombi-
nant vector plus chitosan nanoparticles. Overall, the signifi-
cant down-regulation of CEA, Krt20, and Muc1 tumor mark-
ers in the infused mice by recombinant vector plus chitosan 
nanoparticles (B and E groups) compared with other groups 
was most seen (p < 0.05). In addition, in the healthy mice 
(G group without any treatment), a small amount of tumor 
markers expressions as compared to the treated mice with 
carcinogenic chemicals were observed. In addition, in can-
cerous tissues of BALB/c mice in C and F groups that were 
infused by pBudCE4.1 empty vector (lacking of azurin and 
MAM-A target genes), a considerable expression of tumor 
markers compared to the treated mice with a recombinant 
vector alone or combined with nanoparticles was observed 
(p < 0.05) (Fig. 9).
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Fig. 7  The comparisons of serum levels of IFN-γ, IL-4, IL-12, and 
IL-17A cytokines in infused mice of both prevention and therapy cat-
egories (infused mice with only pBudCE4.1-azurin-MAM-A recom-
binant vector (A and D groups), recombinant vector plus chitosan 
nanoparticles (B and E groups), empty pBudCE4.1 DNA plasmid as 
a control (C and F groups), and without infusion as a normal mice (G 
group)
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Discussion
In this study, the synchronous effects of azurin gene of P. 
aeruginosa and human MAM-A gene were evaluated in 
the stimulation of immune responses against breast cancer 
tumors. For this purpose, the pBudCE4.1-azurin-MAM-A 
gene construct was used for infusion of cancerous BALB/c 
mice that were subjected as prevention and therapy catego-
ries. As regards, the sequence of human MAM-A is simi-
lar to the mouse MAM-A antigen, we used this gene in the 
pBudCE4.1-azurin-MAM-A construct for induction of the 
immune system against breast cancer in BALB/c mice. 
Furthermore, the ultimate goal in the future studies wills 
application of this recombinant vector as a DNA vaccine 
in human.
In infused animals with pBudCE4.1-azurin-MAM-
A recombinant plasmid in both prevention and therapy 
categories (A, B, D, and E groups) compared to the 
injected mice by an empty pBudCE4.1 vector (C and F 
groups), the breast tumor incidence was decreased statis-
tically significantly (p < 0.05). Moreover, the histological 
studies using H&E staining confirmed these results. The 
tumor incidence and weight in animals of prevention cat-
egory were slightly less than the therapy category and it 
was shown that in therapy group after generation of breast 
tumors, the pBudCE4.1-azurin-MAM-A recombinant vec-
tor decreased the diameter of the tumors. Therefore, these 
cancerous mice could be an appropriate animal model for 
investigation of the carcinogenesis effects of chemical 
compounds on human breast tumors and application of 
DNA vaccines. The successful expression of azurin and 
MAM-A genes in the tissues of infusion sites of BALB/c 
mice were observed. The ELISA test demonstrated that 
the serum level of IFN-γ, IL-12, and IL-17A cytokines in 
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Fig. 8  The relative expression comparisons of cytokine genes in 
infused BALB/c mice of both prevention and therapy categories. A 
and D: infused mice by the only pBudCE4.1-azurin-MAM-A recom-
binant vector. B and E: infused mice by pBudCE4.1-azurin-MAM-
A recombinant vector plus chitosan nanoparticles. C and F: infused 
mice by an empty pBudCE4.1 vector. G: non-infused mice (healthy 
group)
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the infused mice by pBudCE4.1-azurin-MAM-A plus chi-
tosan nanoparticles (B and E groups) compared to injected 
animals with only recombinant vector (A and D groups) 
was increased statistically significantly (p < 0.05). These 
findings displayed that chitosan nanoparticles via helping 
to better uptake of plasmid DNA can improve the stimu-
lation of the immune system. In addition, the ELISA test 
manifested that the recombinant vector can increase the 
serum level of these cytokines statistically significantly 
(p < 0.05).
The findings of the real-time PCR indicated that this 
recombinant vector alone or combined with chitosan nano-
particles (A, B, D, and E groups) stimulated the immune 
system via increasing of the IFN-γ, IL-4, IL-12, and IL-
17A cytokine gene expression. However, in infused mice 
by recombinant vector plus nanoparticle, the low difference 
in the rise of the expression level of these cytokine genes 
(except IL-4 and IL-12 interleukins) was observed (p > 0.05). 
The statistically significantly increase of these cytokines in 
the recombinant vector recipient mice observed by molecu-
lar test confirmed the findings of the ELISA assay on incite-
ment of the animals’ immune system. The role of IL-12 in 
breast cancer is tumor suppression and has antitumor activity 
(Tugues et al. 2015). Thus, IFN-γ secretes at the tumor site 
by NK cells and NKT can induce tumor cell death (Alshaker 
and Matalka 2011). In addition, IL-17A is a cytokine pro-
duced by Th17 cells and it is a proinflammatory cytokine in 
the breast tumor environment and correlate with poor prog-
nosis (Cochaud et al. 2013; Esquivel-Velázquez et al. 2015). 
IL-4 is a pleiotropic cytokine produced by T lymphocytes, 
which acts as a potent antitumor activity against various 
tumors (Nagai and Toi 2000; Borj et al. 2017). Therefore, 
the over-expression of these cytokines in the infused ani-
mals by recombinant vector that were observed in this study 
confirms the correct function of this gene construct against 
breast tumor propagation.
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Fig. 9  The tumor marker gene expression in BALB/c mice of pre-
vention and therapy categories. A and D: injected mice by an only 
recombinant vector. B and E: injected mice by recombinant vector 
plus nanoparticles. C and F: injected mice by the pBudCE4.1 (empty 
vector). G: non-injected mice (healthy group)
3 Biotech           (2019) 9:271  
1 3
Page 13 of 15   271 
The results of tumor marker gene expression in the breast 
tissues showed that CEA and Muc1 expressions in injected 
animals by pBudCE4.1-azurin-MAM-A recombinant vec-
tor alone or combined with nanoparticles (A, B, D, and 
E groups) decreased statistically significantly (p < 0.05). 
While, the Krt20 gene expression decreased only in the 
infused mice with a recombinant vector plus chitosan nano-
particles (B and E groups) in both prevention and therapy 
states. These results indicated that in the presence of nano-
particles, the recombinant vector acts better in diminution 
of the tumor marker expression. But until now, the direct 
effects of azurin protein on tumor markers of breast can-
cer (CEA, Muc1, and Krt20 genes) have not been studied. 
Domenici and co-workers described the specific interaction 
of p53 with azurin and they indicated that azurin can enter 
into the cancer cells and via forming a specific and stable 
complex with human p53 which leads to increase of tumor 
suppressor activity (Domenici et al. 2011).
So far, no study has been done to investigate the simul-
taneous effects of azurin gene of P. aeruginosa and human 
MAM-A gene as a DNA vaccine on inhibition of breast can-
cer in laboratory animals. To our knowledge, this is the first 
report of co-application of azurin and MAM-A genes as a 
recombinant vector for prevention and therapy of induced 
breast cancer in exposed BALB/c mice by DMBA and MNU 
chemical compounds. In a study of Yamada et al. 2002, it 
was shown that the bacterial redox protein azurin causes 
the regression of human UISO-Mel-2 tumors xenotrans-
planted in nude mice. They indicated that this protein may 
potentially be used in cancer treatment, whereas in our study, 
the concurrent effects of azurin and human MAM-A as a 
DNA vaccine in the excitation of the immune system of 
BALB/c mice against induced breast cancer tumors were 
evaluated. Our results indicated that breast tumors in ani-
mals that received pBudCE4.1-azurin-MAM-A recombinant 
plasmid alone or combined with nanoparticles inhibited and 
this effect increased in the mice that received the recombi-
nant vector plus chitosan nanoparticles. In one clinical trial 
study by Tiriveedhi and colleagues, the safety and biological 
efficacy of MAM-A DNA vaccine against breast cancer are 
evaluated. After vaccination, in their study, the significant 
increase of the frequency of MAM-A-specific CD8 T cells 
by flow cytometry and the enhanced number of MAM-A-
specific IFNγ-secreting T cells by enzyme-linked immu-
nospot (ELISpot) assay was observed. They indicated that 
the MAM-A DNA vaccine is safe and capable to elect the 
immune system responses, but they suggested that further 
study must be done to evaluate the potential of the MAM-A 
DNA vaccine for breast cancer prevention and/or therapy 
(Tiriveedhi et al. 2014). While, in our study, we used the 
MAM-A and azurin genes together as a DNA vaccine alone 
or combined with chitosan nanoparticles for stimulation 
of the immune system in breast cancerous animal for the 
first time. The effectiveness of pBudCE4.1-azurin-MAM-A 
recombinant plasmid was evaluated by serological (ELISA) 
and molecular (q-real-time PCR) tests. Our findings indi-
cated that in both prevention and therapy categories, this 
recombinant vector can increase the cytokine gene expres-
sion (IFN-γ, IL-4, IL-12, and IL-17A) and also by diminu-
tion of the tumor marker expression (CEA, Muc1, and Krt20 
genes) inhibit the creation and expansion of breast cancer 
tumors. In another study, it was found the potential effects 
of azurin on non-small cell lung cancer (NSCLC) cells 
evaluated and the anticancer effects of this bacterial pro-
tein across several cancer cell lines especially breast cancer 
(Bernardes et al. 2016; Chakrabarty 2014). Therefore, in the 
present research, we used azurin bacteriocin beside human 
MAM-A as a pBudCE4.1-azurin-MAM-A recombinant vec-
tor in two modes which included prevention and therapy of 
breast cancer tumors in induced cancerous BALB/c mice, 
and the positive effects of these target genes on the stimula-
tion of the immune system and inhibition of cancer tumors 
were observed.
Conclusions
The pBudCE4.1-azurin-MAM-A recombinant vector which 
was generated and used in this study, via azurin and MAM-
A genes delivery in BALB/c mice, has a potential ability 
to stimulate the immune system by increasing the cytokine 
gene expression and can inhibit the tumor marker expres-
sion in breast cancer tumors. It is also suggested that further 
studies are required to evaluate the effects and application of 
this recombinant vector as a DNA vaccine on breast cancer 
prevention and/or therapy in animal and human models.
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